QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hosohata, K. Articles by Yamamura, H. I. Search for Related Content PubMed PubMed Citation Articles by Hosohata, K. Articles by Yamamura, H. I.

NEUROPHARMACOLOGY

(2S,3R)-Methyl-2',6'-dimethyltyrosine-L-tetrahydroisoquinoline-3-carboxylic acid [(2S,3R)TMT-L-Tic-OH] Is a Potent, Selective -Opioid Receptor Antagonist in Mouse Brain

Departments of Pharmacology, Chemistry, Biochemistry, Psychiatry, and Medicine and the Sarver Heart Center, University of Arizona, Tucson, Arizona

Received August 13, 2002; accepted October 8, 2002.

	Abstract

Top Abstract Materials and Methods Results Discussion References

 
The constrained opioid peptide (2S,3R)-methyl-2',6'-dimethylty-rosine-L-tetrahydroisoquinoline-3-carboxylic acid [(2S,3R)TMT-L-Tic-OH] exhibits high affinity and selectivity for the -opioid receptors (Liao et al., 1997). In the present study, we examined the pharmacological properties of (2S,3R)TMT-L-Tic-OH in mouse brain. A 5'-O-(3-[³⁵S]thiotriphosphate) ([³⁵S]GTPS) binding assay was used to determine the effect of (2S,3R)TMT-L-Tic-OH on G protein activity in vitro, in mouse brain membranes. -(SNC80; (+)-4-[(R)--((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxy-benzyl]-N,N-diethyl-benzamide) or µ-(DAMGO; [D-Ala², Me-Phe⁴,Gly(ol)⁵]enkephalin) selective opioid full agonists stimulated [³⁵S]GTPS binding in mouse brain membranes 150 ± 4.5% and 152 ± 5.7% over the basal level, respectively. (2S,3R)TMT-L-Tic-OH did not influence basal [³⁵S]GTPS binding in mouse brain membranes but dose dependently shifted the dose-response curve of SNC80 to the right, with a K_e value of 3.6 ± 0.7 nM. In contrast, (2S,3R)TMT-L-Tic-OH had no effect on the dose-response curve of the µ-selective opioid agonist, DAMGO. Warm water (55°C) tail-flick and radiant heat paw-withdrawal tests were used to determine the in vivo nociceptive properties of (2S,3R)TMT-L-Tic-OH in the mouse. Intracerebroventricular injection of (2S,3R)TMT-L-Tic-OH had no significant effect on with-drawal latencies in either nociceptive tests. (2S,3R)TMT-L-Tic-OH (30 nmol/mouse) attenuated deltorphin II- but not DAMGO-mediated antinociception (40 ± 13 and 100% of maximal possible effect, respectively) when administered intracerebroventricularly 10 min before the agonist. Taken together these results suggest that (2S,3R)TMT-L-Tic-OH is a potent highly selective neutral -opioid antagonist in mouse brain.

We have previously synthesized a sterically constrained pseudopeptide opioid ligand, (2S,3R)TMT-L-Tic (Liao et al., 1997), and investigated its pharmacological properties in a recombinant Chinese hamster ovary cell line, stably expressing the human -opioid receptor (hDOR/CHO) (Malatynska et al., 1995). We found that (2S,3R)TMT-L-Tic behaved as a potent inverse agonist in the recombinant hDOR/CHO cells (Hosohata et al., 1999).

To identify the physiologically relevant mechanism of (2S,3R)TMT-L-Tic-OH action however, it is important to determine its pharmacological properties in tissues expressing physiological receptor concentrations, particularly in the central nervous system. In the present study, we examined the effect of (2S,3R)TMT-L-Tic-OH on [³⁵S]GTPS binding in mouse brain membrane preparations. We also determined the effect of (2S,3R)TMT-L-Tic-OH on the potencies and intrinsic activities of -and µ-selective opioid receptor agonists (SNC80 and DAMGO, respectively) in the [³⁵S]GTPS binding assay in mouse brain membranes. A warm water (55°C) tail-withdrawal (tail-flick) test was used to investigate the in vivo effect of (2S,3R)TMT-L-Tic-OH on nociception in mice. In addition, the more sensitive radiant heat paw-withdrawal test was also employed to test the hyperalgesic properties of the compound. Finally, the ability of (2S,3R)TMT-L-Tic-OH to antagonize the antinociception mediated by µ-(DAMGO) and -selective (deltorphin II) opioid receptor agonists was also tested.

	Materials and Methods

Top Abstract Materials and Methods Results Discussion References

 
Chemicals. (2S,3R)TMT-L-Tic-OH was synthesized at the University of Arizona, in the laboratory of Dr. V. J. Hruby (Liao et al., 1997). SNC80 and deltorphin II were obtained from Tocris Pharmaceuticals (Baldwin, MO); DAMGO was purchased from Sigma/RBI (Natick, MA). SNC80 was dissolved in 40% ethanol to obtain a 1 mM stock solution. Deltorphin II was initially prepared as 4 mM stock solution in 20% dimethyl sulfoxide. All other compounds were dissolved in distilled water (tail-flick test) or assay buffer ([³⁵S]GTPS binding assay). Further dilutions were made by distilled water (tail-flick test) or assay buffer ([³⁵S]GTPS binding assay). [³⁵S]GTPS (1250 Ci/mmol) was purchased from PerkinElmer Life Sciences (Boston, MA).

Cell Membrane Preparation. Male ICR mice supplied by Harlan Sprague-Dawley (Indianapolis, IN) were used in this study. The mice were sacrificed by cervical dislocation, whole brains were immediately removed, homogenized in 20 volumes of ice-cold TE buffer (10 mM Tris-HCl, 1.0 mM EDTA, pH 7.4) and centrifuged (40,000g, 15 min) to isolate the crude membrane fraction. Membranes were suspended in 20 volumes of ice-cold assay buffer (25 mM Tris-HCl, 150 mM NaCl, 2.5 mM MgCl₂, 1.0 mM EDTA, 50 µM GDP, 30 µM bestatin, 10 µM captopril, and 0.1 mM phenylmethylsulfonyl fluoride, pH 7.4) and incubated for 30 min at 30°C to remove endogenous agonists. The membranes were centrifuged again as described, and were resuspended in the assay buffer to an optical density of OD₂₈₀ = 0.8.

[³⁵S]GTPS Binding Assay. Mouse brain membranes were incubated with increasing concentrations of (2S,3R)TMT-L-Tic-OH in the presence of 0.1 nM [³⁵S]GTPS (1250 Ci/mmol) in 1.0 ml of assay buffer (25 mM Tris, 150 mM NaCl, 50 µM GDP, 2.5 mM MgCl₂, 1 mM EDTA, 30 µM bestatin, 10 µM captopril, pH 7.4). To assess stimulation of [³⁵S]GTPS binding by full -and µ-opioid receptor agonists in mouse brain membrane preparations, dose-response curves for SNC80 and DAMGO were determined as positive controls. Finally, dose-response curves were measured for SNC80 or DAMGO in the presence of (2S,3R)TMT-L-Tic-OH to determine K_e values for (2S,3R)TMT-L-Tic-OH at mouse brain -and µ-opioid receptors, respectively.

After a 90-min incubation at 30°C, the reaction was terminated by rapid filtration through Whatman GF/B glass fiber filters, followed by four rinses with 4 ml of ice-cold 25 mM Tris/120 mM NaCl, pH 7.4. The filters were soaked in 10 ml of EcoLite7 scintillation cocktail (ICN Biomedicals, Costa Mesa, CA) at 4°C for at least 6 h before bound radioactivity was measured by liquid scintillation spectrophotometry.

Warm (55°C) Water Tail-Withdrawal (Tail-Flick) Nociceptive Test in Mice. Basal tail-withdrawal latencies were determined before administration of the opioid ligands. Mice with basal tail-withdrawal latencies longer than 5 s were excluded from further experiments. Each mouse received the appropriate dose of each compound in 5-µl solution volume, injected into the ventricles. Tail-withdrawal latencies were measured in 10-min intervals, 10 to 60 min after the injection, to determine an antinociceptive time course. Dose-response curves were determined at time points where the antinociceptive effect was maximal (20 min). Mice were assigned 100% antinociception when not responding within 15 s, and their tails were removed from the water to avoid tissue damage. Antinociception was calculated as maximal possible effect (MPE) using the formula: %MPE = (test latency - basal latency) x 100/(15-s basal latency).

Radiant Heat Paw-Withdrawal Hyperalgesic Test in Mice. The method of Hargraeves et al. (1988) was used to determine whether (2S,3R)TMT-L-Tic-OH mediates hyperalgesia in mice. Mice (n = 8) were allowed to habituate to Plexiglas enclosures (2 x 3 inches) on a clear glass plate maintained at 30°C (Hargraeves box, purchased from Dr. T. Yaksh, University of California San Diego, CA). Baseline paw-withdrawal threshold values were determined by focusing a radiant heat source (high intensity projector lamp) onto the plantar surface of the hindpaw. Paw-withdrawal exposed a photocell that automatically turned off both the heat source and a timer. A cutoff of 30 s was used to prevent damage to the irradiated paw. (2S,3R)TMT-L-Tic-OH (30 nmol) was administed through i.c.v. route 1 h after the baseline paw-withdrawal test, and paw-withdrawal latencies were determined 15, 30, 45, and 60 min after the injection. A significant reduction in paw-withdrawal latency from the baseline value was interpreted as thermal hypersensitivity. Data were analyzed by one-way analysis of variance and significance was set at p 0.05.

Data Analysis. [³⁵S]GTPS binding data were analyzed as fixed (n_H = 1) slope sigmoidal dose-response curves using Prism Version 2 (San Diego, CA). The K_e value of (2S,3R)TMT-L-Tic-OH at the -opi-oid receptor was calculated using the Schild equation: K_e = [antagonist]/DR-1 (Arunlakshana and Schild, 1959), where DR indicates dose ratio between the EC₅₀ values of an agonist (SNC80) in the absence and presence, respectively, of an antagonist [(2S,3R)TMT-L-Tic-OH, 100 nM]. Since the dose-response of DAMGO was not significantly shifted in the presence of 3000 nM (2S,3R)TMT-L-Tic-OH, the exact K_e value of (2S,3R)TMT-L-Tic-OH at the µ-opioid receptor was not determined.

	Results

Top Abstract Materials and Methods Results Discussion References

 
We have reported previously (Hosohata et al., 1999) that (2S,3R)TMT-L-Tic-OH behaves as an inverse agonist in the functional [³⁵S]GTPS binding assay in CHO cells overexpressing the human -opioid receptor. The present work was designed to determine the pharmacological properties of (2S,3R)TMT-L-Tic-OH in mouse brain using in vitro and in vivo functional assays.

The [³⁵S]GTPS binding assay was used to investigate the effect of (2S,3R)TMT-L-Tic-OH on the nucleotide exchange rate of the G proteins in vitro in mouse brain membrane preparations. Opioid full agonists, selective for the -(SNC80) or µ-(DAMGO) opioid receptors (Quock et al., 1999), were used as controls to verify that functional receptor-G protein interaction is maintained in the mouse brain membrane preparations. As shown in Fig. 1, SNC80 and DAMGO stimulated [³⁵S]GTPS binding in mouse brain membranes 150 ± 4.5 and 152 ± 5.7% over the basal level, respectively. The EC₅₀ values of SNC80 and DAMGO were 246 ± 20 and 1460 ± 630 nM, respectively. In contrast, (2S,3R)TMT-L-Tic-OH up to 30 µM concentration did not influence basal [³⁵S]GTPS binding, indicating that (2S,3R)TMT-L-Tic-OH is a neutral antagonist in mouse brain membrane preparations (Fig. 1).

View larger version (16K): [in this window] [in a new window]   Fig. 1. The effect of SNC80, DAMGO and (2S,3R)TMT-L-Tic on [35S]GTPS binding in mouse brain membrane preparations. Mouse brain membrane preparations were incubated (90 min, 30°C) with increasing concentrations of SNC80 (), DAMGO (), or (2S,3R)TMT-L-Tic-OH (F) in [35S]GTPS assay buffer containing 0.1 nM [35S]GTPS, 100 mM NaCl, and 50 µM GDP. SNC80 and DAMGO stimulated [35S]GTPS binding in mouse brain membranes 150 ± 4.5 and 152 ± 5.7% over the basal level with EC50 values of 246 ± 20 and 1460 ± 630 nM, respectively. Each point represents mean ± S.E.M. from n = 3 independent experiments, performed in duplicate.

Additionally, (2S,3R)TMT-L-Tic-OH dose dependently shifted to the right of the dose-response curve of SNC80 in the [³⁵S]GTPS binding assay (Fig. 2A). The potency of (2S,3R)TMT-L-Tic-OH at the -opioid receptor, as determined using the Schild equation, was K_e = 3.61 ± 0.71 nM. In contrast, (2S,3R)TMT-L-Tic-OH had no significant effect on the dose-response curve of the µ-opioid agonist, DAMGO, in the [³⁵S]GTPS binding assay in mouse brain membranes (Fig. 2B). Therefore, the K_e value of (2S,3R)TMT-L-Tic-OH at the -opioid receptor can be estimated to be at least 800-fold lower than its K_e value at the µ-opioid receptor (>3000) in mouse brain.

View larger version (21K): [in this window] [in a new window]   Fig. 2. Dose-response curves for stimulation of [35S]GTPS binding by SNC80 (A) and DAMGO (B) in the presence of increasing concentrations of (2S,3R)TMT-L-Tic in mouse brain membrane preparations. Mouse brain membrane preparations were incubated (90 min, 30°C) with increasing concentrations of SNC80 (filled symbols) (A) or DAMGO (open symbols) (B) in the absence (E, F) or presence of 10 (), 100 (), 300 (), 1000 (), or 3000 (diao) nM of (2S,3R)TMT-L-Tic-OH in [35S]GTPS assay buffer containing 0.1 nM [35S]GTPS, 100 mM NaCl, and 50 µM GDP. Each point represents mean ± S.E.M. The Ke value of (2S,3R)TMT-L-Tic-OH at the -and µ-opioid receptors, calculated according to the Schild equation was 3.6 ± 0.7 and >3000 nM, respectively.

The in vivo properties of (2S,3R)TMT-L-Tic-OH were investigated using the warm (55°C) water tail-withdrawal (tail-flick) nociceptive and the radiant heat paw-withdrawal hyperalgesic tests in mice. As seen in Fig. 3, i.c.v. injection of -(deltorphin II, Fig. 3A) or µ-(DAMGO, Fig. 3B) opioid receptor agonists increased tail-flick latencies in mice. Antinociception was maximal 20 min after i.c.v. administration of either agonist, in doses 10 nmol/mouse for deltorphin II and 0.02 nmol/mouse for DAMGO. In contrast, as seen in Fig. 4, (2S,3R)TMT-L-Tic-OH individually had no measurable effect on tail-withdrawal latencies. The lack of effect of (2S,3R)TMT-L-Tic-OH persisted throughout the examined time interval (60 min) after i.c.v. administration of the compound (Fig. 4) for doses up to 30 nmol/mouse.

View larger version (29K): [in this window] [in a new window]   Fig. 3. The time course of deltorphin II- (A) and DAMGO-mediated (B) antinociception in mouse tail-flick test. Groups of mice (n = 7–11) received i.c.v. injection of vehicle (), 3 (), 10 (), 20 nmol () of deltorphin II (A) or vehicle (), 0.006 (), 0.02 (), 0.2 () nmol of DAMGO (B) in 5-µl injection volume. Tail-withdrawal latencies were measured by immersion of the tail of the mice in a 55°C water bath. Mice were assigned 100% antinociception when not responding within 15 s. Antinociception was calculated using the formula: %MPE = (test latency - basal latency) x 100/(15-s basal latency).

View larger version (20K): [in this window] [in a new window]   Fig. 4. Intracerebroventricular injection (2S,3R)TMT-L-Tic has no effect on mouse tail-flick latencies. Groups of mice (n = 4 each) received i.c.v. injections of distilled water () or 10 (), 20 (), 30 nmol () of (2S,3R)TMT-L-Tic in 5-µl injection volume. Tail-withdrawal latencies were tested in 10-min intervals after the injection by the immersion of the tail of the mice in a 55°C water bath. Mice were assigned 100% antinociception when not responding within 15 s. Antinociception was calculated using the formula: %MPE = (test latency - basal latency) x 100/(15-s basal latency).

Putative hyperalgesic properties of (2S,3R)TMT-L-Tic-OH were also tested in the more sensitive radiant heat paw-withdrawal test in mice (Hargraeves et al., 1988). The mean paw-withdrawal threshold in vehicle-injected control mice was 10.4 ± 0.6 s. Intracerebroventricular injection of (2S,3R)TMT-L-Tic-OH (30 nmol/mouse) had no measurable effect (one-way analysis of variance, p = 0.42, nonsignificant) on paw-withdrawal latencies in this highly sensitive hyperalgesic test (Fig. 5). An established cannabinoid CB₁ receptor inverse agonist (SR141,716) was used as a positive control (Richardson et al., 1997) in the assay. We found that SR141,716 (1 nmol/mouse) reduced paw-withdrawal latencies by approximately 50% 5 min after i.c.v. administration (data not shown), indicating that the method is sensitive enough to detect hyperalgesia by an established CB₁ receptor inverse agonist (Landsman et al., 1997).

View larger version (12K): [in this window] [in a new window]   Fig. 5. Intracerebroventricular injection of (2S,3R)TMT-L-Tic has no effect on mouse paw-withdrawal latencies in the radiant heat paw-withdrawal hyperalgesia assay. Paw-withdrawal latencies were in response to radiant heat stimulus focused to the plantar surface of the hindpaw were determined for n = 8 mice, 1 h before (baseline) and at selected intervals after i.c.v. administration of 30 nmol (2S,3R)TMT-L-Tic. Basal latency was 10.4 ± 0.6 s. A cutoff of 40 s was employed to prevent tissue damage.

Finally, the selectivity of (2S,3R)TMT-L-Tic-OH (30 nmol/mouse) to antagonize antinociception mediated by -or µ-opioid receptor agonists was also investigated. To establish agonist doses necessary and sufficient to achieve maximal possible antinociceptive effect (MPE) in the tail-flick test 20 min after i.c.v. adminstration, dose-response curves were determined for the -selective agonist deltorphin II or the µ-selective agonist DAMGO. Both deltorphin II and DAMGO produced maximal antinociception 20 min after i.c.v. injection, with A₅₀ values of 8.55 and 0.074 nmol/mice, respectively. Therefore, in subsequent experiments, mice received i.c.v. injection of a high dose of (2S,3R)TMT-L-Tic-OH (30 nmol/mouse) 10 min prior to i.c.v. administration of the previously determined optimal doses of either deltorphin II (20 nmol/mouse) or DAMGO (0.2 nmol/mouse). Tail-flick latencies were determined 20 min after the injection of the agonists. As shown in Fig. 6, pretreatment of mice with 30 nmol (2S,3R)TMT-L-Tic-OH reduced deltorphin II-mediated antinociception (40 ± 13% MPE, p < 0.05) but had no effect on DAMGO-mediated antinociception.

View larger version (46K): [in this window] [in a new window]   Fig. 6. The effect of (2S,3R)TMT-L-Tic on deltorphin-and DAMGO-mediated antinociception in mouse tail-flick test. Groups of mice (n = 8) received i.c.v. injection of 30 nmol of (2S,3R)TMT-L-Tic-OH in 5-µl injection volume 10 min before i.c.v. deltorphin II (20 nmol, filled bars) or DAMGO (0.2 nmol, patterned bars) injection in 5-µl solution volume. Tail-withdrawal latencies were tested in a 55°C water bath, 20 min after injection of the agonists. Antinociception was calculated as MPE ± S.E.M.

	Discussion

Top Abstract Materials and Methods Results Discussion References

 
Selective -opioid receptor antagonists can be used as pharmacological tools to identify unique physiological functions of the -opioid receptors and may subsequently serve as therapeutic agents to regulate those functions in vivo. Selective -opioid antagonists were shown to modulate the development of tolerance and dependence to opiate agonists (Abdelhamid et al., 1991; Fundytus et al., 1995) and to diminish the reinforcing effects of cocaine (Menkens et al., 1992) and ethyl alcohol (Froehlich et al., 1998). -Opioid antagonists may also have therapeutic value as immunosuppressants in organ transplants (House et al., 1995) and in chronic inflammatory diseases, such as rheumatoid arthritis (Spetea et al., 2001).

Structure-activity studies on morphinane-and enkephalin-based opioids led to the development of nonpeptidic and peptidic opioid antagonists with improved selectivity for the -opioid receptor. Thus, introduction of steric constraints into the prototype -opioid peptide antagonist, N,N-diallyl-Leu-enkephalin (Shaw et al., 1982), yielded metabolically stable pseudopeptide antagonists, such as ICI 174,864 (Cotton et al., 1984), TIPP (Schiller et al., 1992), TIPP (Schiller et al., 1993), and Tyr-Tic (Salvadori et al., 1995), with progressively increasing -selectivity. In the second generation of pseudopeptide opioid antagonists, additional steric constraints were introduced by the use of methylated Tyr analogs, leading to further improved -selectivity, such as DMT-L-Tic (Salvadori et al., 1995, 1997) and TMT-L-Tic (Liao et al., 1997).

We have previously isolated the stereoisomers of the highly constrained opioid dipeptide TMT-L-Tic-OH to study the effects of steric and topographic constraints on the affinity, selectivity, and functional properties of the opioid pharmacophore. The most selective stereoisomer, (2S,3R)TMT-L-Tic-OH, competed with high affinity (IC₅₀ 9.3 ± 0.53 nM) for [³H]p-Cl-DPDPE, but not for [³H]DAMGO (IC₅₀ 35,000 ± 18,000) binding sites in rat brain membrane preparations (Liao et al., 1997). Similar affinity and selectivity values were obtained for (2S,3R)TMT-L-Tic-OH in recombinant CHO cell lines, expressing human -or µ-opioid receptors (K_i = 5.2 ± 0.8 and 33,600 ± 4,340 nM, respectively; unpublished data).

Subsequently, we reported that (2S,3R)TMT-L-Tic behaves as a potent full inverse agonist in a recombinant Chinese hamster ovary cell line (hDOR/CHO), stably expressing a high number of human -opioid receptors per cell (1800 ± 150 fmol/million cells). (2S,3R)TMT-L-Tic-OH inhibited basal [³⁵S]GTPS binding in hDOR/CHO cells with an intrinsic activity similar to that of the prototype -opioid receptor inverse agonist, ICI 174,864 (E_max = 42 versus 47.8% of basal, respectively), but had 78-fold higher potency (Hosohata et al., 1999).

According to the two-state ternary complex model of receptor activation (Samama et al., 1993), G protein-coupled receptors exist in equilibrium between inactive and active receptor conformations. The active receptor conformation is able to activate G proteins, leading to signal transduction. The propensity of a receptor to convert from inactive to active conformation in the absence of ligand (constitutive activity) is determined by the structure of the receptor. Some receptors have been shown to exhibit measurable constitutive activity in physiological tissue preparations (reviewed by de Ligt et al., 2000), whereas for others spontaneous isomerization to the active state is more strongly restricted.

The ability of different ligands to perturb the equilibrium between inactive and active receptor conformations is described by a ligand-specific equilibrium constant , the microscopic equivalent of efficacy (Onaran and Costa, 1997). Ligands with values >1 are agonists that shift the equilibrium into the direction of the active ternary complex. Inverse agonists ( < 1) have higher affinity to the inactive receptor conformation and will shift the equilibrium in the opposite direction, whereas neutral agonists ( = 1) have no effect on the equilibrium.

Experimental manipulations, such as overexpression of the receptor or the appropriate G proteins, or the presence of low sodium or GDP concentrations in the assay buffer, were shown to increase constitutive receptor activity (Strange, 2002). In addition, a number of point mutations have been identified that increased constitutive GPCR activity. Some of these mutants have been implicated in the pathophysiology of diseases (reviewed in de Ligt et al., 2000). Recently, a number of drugs that were previously considered neutral antagonists were shown to exhibit inverse agonist properties in recombinant cells expressing very high receptor densities.

The relevance of inverse agonism in tissues expressing lower physiological receptor concentrations, however, is still not fully understood (de Ligt et al., 2000). Therefore, it is of interest to examine the pharmacological properties of (2S,3R)TMT-L-Tic-OH in the central nervous system to determine its mechanism of action in vivo. In the present study, we examined the pharmacological properties of (2S,3R)TMT-L-Tic-OH in mouse brain. Interestingly, (2S,3R)TMT-L-Tic-OH behaved as a neutral -opioid receptor antagonist in mouse brain, exhibiting high potency in vitro in the [³⁵S]GTPS binding assay and high selectivity in both in vitro and in vivo (warm water tail-flick) pharmacological assays.

Thus, (2S,3R)TMT-L-Tic-OH did not influence basal [³⁵S]GTPS binding in mouse brain membranes. (2S,3R)TMT-L-Tic-OH also had no significant effect on tail withdrawal latencies when administered alone. Similar to (2S,3R)TMT-L-Tic-OH, the prototype -opioid receptor inverse agonist ICI 174,864, also had no effect on basal [³⁵S]GTPS binding in rat cerebral cortex and striatum cell membranes (Rouleau et al., 2002), indicating that the expression level of the -opioid receptor in whole brain homogenates does not reach the threshold level to produce measurable constitutive activity in this assay. Interestingly however, Georgoussi and Zioudrou (1993), using ³²P as radiolabel, were able to show a 10% inhibition of high affinity GTPase activity by 1 µM ICI 174,864 in rat brain membranes.

Physiological tissue preparations usually consist of mixed populations of cells, each expressing different receptor concentrations. Thus, although (2S,3R)TMT-L-Tic-OH did not influence basal G protein activity in whole brain homogenates and showed no nociceptive response in the tail-flick assay, it is still conceivable that a more sensitive assay would detect inverse agonism in responses mediated in critical brain regions that express high -opioid receptor density. Nociceptive tests based on changes in paw-withdrawal latency in response to thermal nociceptive stimuli have proven to be more sensitive for the detection of hyperalgesic responses than the warm water tail-flick assay (Richardson et al., 1997). Therefore, we also used the radiant heat paw-withdrawal latency assay to test whether (2S,3R)TMT-L-Tic-OH exhibited any inverse agonist (hyperalgesic) properties in vivo in mice. Intracerebroventricular injection of (2S,3R)TMT-L-Tic-OH (30 nmol/mouse), however, had no measurable effect on paw-withdrawal latencies in the highly sensitive radiant heat paw-withdrawal hyperalgesic test. The CB₁ cannabinoid receptor inverse agonist, SR 141,716, on the other hand was able to produce hyperalgesia in this test. The difference is likely due to the 10 times higher density of CB₁ receptors in brain.

(2S,3R)TMT-L-Tic-OH on the other hand dose dependently shifted the dose-response curve of a -selective opioid receptor agonists in the [³⁵S]GTPS binding assay with a K_e value of 3.6 ± 0.7 nM. Conversely, the dose-response curve of the µ-selective opioid agonist, DAMGO was not altered in the presence of (2S,3R)TMT-L-Tic-OH. Moreover, i.c.v. injection of (2S,3R)TMT-L-Tic-OH 10 min before administration of opioid receptor agonists antagonized deltorphin II-mediated antinociception in the warm water tail-withdrawal test in mice but had no effect on DAMGO-mediated antinocicepton even at a high (30 nmol) dose.

These results indicate that (2S,3R)TMT-L-Tic-OH is a potent highly selective neutral -opioid antagonist in mouse brain membrane preparations in vitro and a selective neutral -opioid antagonist in mouse brain in vivo. (2S,3R)TMT-L-Tic therefore, may serve as a useful pharmacological and therapeutic agent, to characterize and modulate -opioid receptor-regulated physiological functions.

	Footnotes

 
This work was supported in part by grants from the U.S. Public Health Service and from the National Institute of Drug Abuse (DA06284 and DA13449).

DOI: 10.1124/jpet.102.042929.

ABBREVIATIONS: (2S,3R)TMT-L-Tic-OH, (2S,3R)-methyl-2',6'-dimethyltyrosine-L-tetrahydroisoquinoline-3-carboxylic acid; hDOR, human -opioid receptor; CHO, Chinese hamster ovary; [³⁵S]GTPS, guanosine-5'-O-(3-[-[³⁵S]thio)triphosphate; SNC80, (+)-4-[(R)--((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxy-benzyl]-N,N-diethylbenzamide; DAMGO, [D-Ala²,Me-Phe⁴,Gly(ol)⁵]enkephalin; K_e, dissociation constant from Schild analysis; MPE, maximal possible effect; DPDPE, [D-Pen²,D-Pen⁵]-enkephalin; ICI 174,864, N,N-diallyl-Tyr-Aib-Aib-Phe-Leu-OH; SR 141,716, N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboximide hydrochloride.

Address correspondence to: Dr. Henry I. Yamamura, Department of Pharmacology, College of Medicine, University of Arizona Health Sciences Center, Tucson, AZ 85724. E-mail: hiy{at}u.arizona.edu

	References

Top Abstract Materials and Methods Results Discussion References

 

Abdelhamid EE, Portoghese PS, Sultana M, and Takemori AE (1991) Selective blockade of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J Pharmacol Exp Ther 258: 299–303.[Abstract/Free Full Text]

Arunlakshana O and Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol Chemother 14: 49–58.

Cotton R, Shaw JS, Miller L, Giles MG, and Timms D (1984) ICI 174864: a highly selective antagonist for the opioid delta-receptor. Eur J Pharmacol 97: 331–339.[CrossRef][Medline]

Cowell SM, Balse-Srinivasan PM, Ahn J-M, and Hruby VJ (2002) Design and synthesis of peptide antagonists and inverse agonists for G protein-coupled receptors. Methods Enzymol 343: 49–72.[Medline]

de Ligt RAF, Kourounakis AP, and IJzerman AP (2000) Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery. Br J Pharmacol 130: 1–12.[CrossRef][Medline]

Froehlich JC, McCullough DE, Zink RW, Badia-Elder NE, and Portoghese PS (1998) Contribution of the opioid system to alcohol aversion and alcohol drinking behavior. J Pharmacol Exp Ther 287: 284–292.[Abstract/Free Full Text]

Fundytus ME, Weltrowska G, Shapiro M, Schiller PW, and Coderre TJ (1995) Attenuation of morphine tolerance and dependence with the highly selective -opioid receptor antagonists TIPP[]. Eur J Pharmacol 286: 105–108.[CrossRef][Medline]

Georgoussi Z and Zioudrou C (1993) Effect of delta-opioid antagonists on the functional coupling between opioid receptors and G-proteins in rat brain membranes. Biochem Pharmacol 45: 2405–2410.[CrossRef][Medline]

Hargraeves K, Dubner R, Brown F, Flores C, and Joris J (1988) A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32: 77_-88.[CrossRef][Medline]

Hosohata K, Burkey TH, Alfaro-Lopez J, Hruby VJ, Roeske WR, and Yamamura HI (1999) (2S,3R)TMT-L-Tic is a potent inverse agonist at the human -opioid receptor. Eur J Pharmacol 380: R9–R10.[CrossRef][Medline]

House RV, Kozak JT, Thomas PT, and Bhargava H (1995) Suppression of immune function by non-peptidic delta-opioid receptor antagonists. Neurosci Lett 198: 119–122.[CrossRef][Medline]

Knapp RJ, Malatynska E, Collins N, Fang L, Wang JY, Hruby VJ, Roeske WR, and Yamamura HI (1995) Molecular biology and pharmacology of cloned opioid receptors. FASEB J 9: 516–525.[Abstract]

Landsman RS, Burkey TH, Consroe P, Roeske WR, and Yamamura HI (1997) SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur J Pharmacol 334: R1–R2.[CrossRef][Medline]

Liao S, Yamamura HI, Porreca F, Qui W, Davis P, Hosohata K, Han Y, Shenderovich MD, Lin J, and Hruby VJ (1997) The stereochemical requirements of the novel -opioid selective dipeptide antagonist TMT-TIC. Bioorg Med Chem Lett 7: 3049–3052.[CrossRef]

Malatynska E, Roeske WR, Waite S, Li X, Santoro G, Knapp RJ, Wang Y, and Yamamura HI (1995) Human opioid receptor: a stable cell line for functional studies of opioids. NeuroReport 6: 613–616.[Medline]

Menkens K, Reid LD, Portoghese PS, Wild KD, Bilsky EJ, and Porreca F (1992) Cocaine place preference is blocked by the -opioid receptor antagonist, naltrindole. Eur J Pharmacol 219: 345–346.[CrossRef][Medline]

Onaran HO and Costa T (1997) Agonist efficacy and allosteric models of receptor action. Ann NY Acad Sci 812: 98–115.

Quock RM, Burkey TH, Varga EV, Hosohata Y, Hosohata K, Cowell SM, Slate CA, Ehlert FJ, Roeske WR, and Yamamura HI (1999) The -opioid receptor: molecular pharmacology, signal transduction and the determination of drug efficacy. Pharmacol Rev 51: 503–532.[Abstract/Free Full Text]

Richardson JD, Aanonsen L, and Hargreaves KM (1997) SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur J Pharmacol 319: R3–R4.[CrossRef][Medline]

Rouleau A, Ligneau X, Tardivel-Lacombe J, Morisset S, Gbahou F, Schwartz J-C, and Arrang J-M (2002) Histamine H₃-receptor-mediated [³⁵S]GTPS binding: evidence for constitutive activity of the recombinant and native rat and human H₃ receptors. Br J Pharmacol 135: 383–392.[CrossRef][Medline]

Salvadori S, Attila M, Balboni G, Bianchi C, Bryant SD, Crescenzi O, Guerrini R, Picone D, Tancredi T, and Temussi PA (1995) Delta opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides. Mol Med 1: 678–689.[Medline]

Salvadori S, Balboni G, Guerrini R, Tomatis R, Bianchi C, Bryant SD, Cooper PS, and Lazarus LH (1997) Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary opioid antagonist activity. J Med Chem 40: 3100–3108.[CrossRef][Medline]

Samama P, Cotecchia S, Costa T, and Lefkowitz RJ (1993) A mutation-induced activated state of the ₂-adrenergic receptor: Extending the ternary complex model. J Biol Chem 268: 4625–4636.[Abstract/Free Full Text]

Schiller PW, Lemieux C, Marsden BJ, Wilkes BC, Weltrowska G, Nguyen TM-D, and Chung NN (1992) Differential stereochemical requirements of µ vs. opioid receptors for ligand binding and signal transduction: development of a class of potent and highly -selective peptide antagonists. Proc Natl Acad Sci USA 89: 11871–11875.[Abstract/Free Full Text]

Schiller PW, Weltrowska G, Nguyen TM, Wilkes BC, Chung NN, and Lemieux C (1993) TIPP[psi]: a highly potent and stable pseudopeptide delta opioid receptor antagonist with extraordinary delta selectivity. J Med Chem 36: 3182–3187.[CrossRef][Medline]

Shaw JS, Gormley JJ, Turnbull JJ, Miller L, and Morley JS (1982) Selective antagonists at the opiate delta-receptor. Life Sci 31: 1259–1262.[CrossRef][Medline]

Spetea M, Erlandsson-Harris H, Berzetei-Gurske IP, Klareskog L, and Schmidhammer H (2001) Binding, pharmacological and immunological profiles of the -selective opioid receptor antagonist HS 378. Life Sci 69: 1775–1782.[CrossRef][Medline]

Strange PG (2002) Mechanism of inverse agonism at G-protein-coupled receptors. Trends Pharmacol Sci 23: 89–95.[CrossRef][Medline]

This Article Abstract Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hosohata, K. Articles by Yamamura, H. I. Search for Related Content PubMed PubMed Citation Articles by Hosohata, K. Articles by Yamamura, H. I.